Assistant Professor of Medicine
Hematology
Dr. Brad S. Kahl, MD
|
|
Give Review
Brad Kahl works in the field of Hematology. He studied medicine at Tufts University School of Medicine. Tufts University School of Medicine is ranked 49/52 in Research/PrimaryCare. He over the years received 2 awards: "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Brad Kahl is a published physician. He has 74 papers published. The most current publication "Follicular lymphoma: evolving therapeutic strategies." Brad Kahl accepts Medicare.
Publications
- Rituximab extended schedule or retreatment trial for low tumour burden non-follicular indolent B-cell non-Hodgkin Lymphomas: Eastern Cooperative Oncology Group Protoco...
- Bendamustine + rituximab chemoimmunotherapy and maintenance lenalidomide in relapsed, refractory Chronic lymphocytic leukaemia and small lymphocytic lymphoma: A Wiscon...
- Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin Lymphoma in the modern era.
- Personalized risk prediction for event-free survival at 24 months in patients with diffuse large b-cell Lymphoma.
- Fc gamma receptor 3A and 2A polymorphisms do not predict response to rituximab in follicular Lymphoma.
- Anxiety and Health-Related Quality of Life Among Patients With Low-Tumor Burden Non-Hodgkin Lymphoma Randomly Assigned to Two Different Rituximab Dosing Regimens: Resu...
- A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell Lymphoma.
- Emerging Therapy for the Treatment of Mantle Cell Lymphoma.
- Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular Lymphoma: a wisconsin oncology network study.
- Rituximab Extended Schedule or Re-Treatment Trial for Low-Tumor Burden Follicular Lymphoma: Eastern Cooperative Oncology Group Protocol E4402.
- A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: Correlation between clinical responses and...
- Recent advances in mantle cell Lymphoma: report of the 2013 Mantle Cell Lymphoma Consortium Workshop.
- Results of a phase I study of idelalisib, a PI3Kδ inhibitor, in patients with relapsed or refractory mantle cell Lymphoma (MCL).
- Idelalisib, an inhibitor of phosphatidylinositol 3 kinase p110δ, for relapsed/refractory chronic lymphocytic Leukemia.
- Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin Lymphoma.
- High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell Lymphoma.
- Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study.
- Central nervous system involvement in diffuse large B-cell Lymphoma: an analysis of risks and prevention strategies in the post-rituximab era.
- Bulky Aggressive B-Cell Lymphoma: To Radiate or Not to Radiate--That Is the Question.
- PI3Kdelta Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma.
- Phase II study of VcR-CVAD with maintenance rituximab for untreated mantle cell Lymphoma: an Eastern Cooperative Oncology Group Study (E1405).
- PI3-Kinase Inhibitors in Chronic Lymphocytic Leukemia.
- Integrating emerging treatment options in mantle cell Lymphoma: general discussion.
- Frontline Management Strategies for Older MCL Patients.
- Integrating emerging treatment options in mantle cell Lymphoma: introduction.
- Autologous transplantation as consolidation for aggressive non-Hodgkin's Lymphoma.
- Targeting BTK with ibrutinib in relapsed or refractory mantle-cell Lymphoma.
- Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-Cell or natural killer Cell neoplasms: an East...
- Immunohistochemical evaluation of MYC expression in mantle cell Lymphoma.
- Recent advances in mantle cell Lymphoma: report of the 2012 Mantle Cell Lymphoma Consortium Workshop.
- Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin Lymphoma: correlative analysis from a large North American co-operative group trial.
- Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Co...
- Patients with diffuse large B-cell Lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an Internat...
- The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin Lymphoma patients: a comprehensive analysis from the N...
- Is there a role for "watch and wait" in follicular Lymphoma in the rituximab era?
- The Future of B-Cell Lymphoma Therapy: The B-Cell Receptor and its Downstream Pathways.
- Microscale functional cytomics for studying hematologic cancers.
- Bendamustine: more ammunition in the battle against mantle cell Lymphoma.
- Current Status of Targeted Therapies for Mantle Cell Lymphoma.
- Maintenance Rituximab in Follicular Non-Hodgkin Lymphoma: Facts and Controversies.
- Cardiac Toxicity Associated with Bevacizumab (Avastin) in Combination with CHOP Chemotherapy for Peripheral T Cell Lymphoma in ECOG 2404 Trial.
- VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell Lymphoma: a Wisconsin Oncology Network study.
- Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study.
- Maintenance rituximab following induction chemo-immunotherapy for mantle cell Lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network.
- Treatment of synchronous mantle cell Lymphoma and small lymphocytic Lymphoma with bendamustine and rituximab.
- Use of tissue microarray and automated quantitative analysis for screening and validation of potential biomarkers in mantle cell Lymphoma.
- Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin Lymphoma.
- Autologous versus Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation for Patients with Chemosensitive Follicular Non-Hodgkin Lymphoma beyond First Complet...
- Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell Lymphoma in the elderly: a Wisconsin oncology network study.
- Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell Lymphoma.
- Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
- Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin Lymphoma: results from a Multicenter Study.
- Frontline therapy in mantle cell Lymphoma: the role of high-dose therapy and integration of new agents.
- Outcomes of patients with Burkitt Lymphoma older than age 40 treated with intensive chemotherapeutic regimens.
- Bortezomib in patients with relapsed or refractory mantle cell Lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study.
- Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell Lymphoma: an international collaborative study.
- Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma Cells.
- Thalidomide maintenance following high-dose melphalan with autologous stem Cell support in myeloma.
- Special problems in B-cell Lymphoma: an historical perspective.
- Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell Lymphoma.
- A 5-drug regimen maximizing the dose of cyclophosphamide is effective therapy for adult Burkitt or Burkitt-like Lymphomas.
- A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untr...
- Two new indications for rituximab.
- Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell Lymphoma.
- Indolent Lymphomas: current and emerging treatment approaches.
- Eastern Cooperative Oncology Group 4402: Rituximab Extended Schedule or Retreatment Trial (RESORT).
- Follicular Lymphoma: management options in the era of targeted therapy.
- Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's Macroglobulinemia.
- Phase II study of weekly low-dose paclitaxel for relapsed and refractory non-Hodgkin's Lymphoma: a Wisconsin Oncology Network Study.
- Update: gastric MALT Lymphoma.
- A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell Lymphoma: an eastern cooperative oncology group study (E1404).
- A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell Lymphoma (DLBCL) and correlative analyses of patient-specific factors.
- Follicular Lymphoma: evolving therapeutic strategies.
Schools
Tufts University
Procedures Preformed
- Plasmapheresis
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Chronic Myeloid Leukemia (CML)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
University of Wisconsin -
Tufts University School of Medicine
Hospital
-
University of Wisconsin Hospital and Clinics -
Barnes-Jewish Hospital
Drug Facts
| NPI NUMBER | 1407822430 | |
| NPPES Provider LastName | KAHL | |
| NPPES Provider FirstName | BRAD | |
| NPPES Provider ZIPCode | 53792 | |
| NPPES Provider State | WI | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 319.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1407822430 |
| Last Name Of The Provider | KAHL |
| First Name Of The Provider | BRAD |
| View All |
Similar Doctors
|
|
Dr. Amit Sanyal, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Natalie S. Callander, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vaishalee P. Kenkre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Peiman Hematti, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. William J. Hisgen, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Erik A. Ranheim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David T. Yang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ryan F. Porter, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jingnan Xiao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Catherine P. Leith, MB BCH
This Doctor is OpenDoctor Recommended.
|